TOKYO, June 3, 2025 - (JCN Newswire via SeaPRwire.com) - Anime Tokyo Station is an anime exhibition site focused on Japanese anime content, which has developed a devoted fan base around the world. It attracts 167,410 visitors (as of May 18, 2025), children and adults alike, from both Japan and overseas. We are pleased to announce the launch of the official Anime Tokyo Station YouTube channel, along with the release of a new promotional video narrated by renowned voice actor Akio Otsuka, introducing the facility.Promotional video narrated by Akio OtsukaAs you wander freely through the interior spaces of Anime Tokyo Station, you’ll encounter striking symbolic displays, special exhibitions that showcase the appeal of Japanese anime, archived materials, and a variety of services on each floor. Enjoy a leisurely tour of the facility with narration by renowned voice actor Akio Otsuka.Going forward, the official Anime Tokyo Station YouTube channel will regularly share new videos, including further introductions to the facility, as well as coverage of special exhibitions, workshops, and events. The channel aims to serve as a hub for anime exhibitions and keep viewers informed about Anime Tokyo Station’s ongoing initiatives.YouTube overviewChannel name: Anime Tokyo Station Official ChannelChannel URL: https://www.youtube.com/channel/UCSJOjGJE5Yiqw3PZ97AVdJwFacility Introduction Video: https://www.youtube.com/watch?v=1jp-OK_Kfe8Venue Overview- Name: Anime Tokyo Station (also known as "Anime Tokyo")- Location: Floors B1 to 2F of Tokyu East 5 (2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo)*4 minutes on foot from the East Exit of Ikebukuro Station- Hours: 11:00 a.m. to 7:00 p.m. (last admission: 6:45 p.m.)- Closed: Mondays*If Monday falls on a holiday, the venue will be open on Monday and closed on the following dayNew Year's holiday periodMay be closed on other daysPlease check the venue website before coming.- Admission fee: Free- Website: https://animetokyo.jp/en/ Inquiries regarding this press releasePublic Relations Office of "Anime Tokyo Station" (Kyodo PR)Contact person: Miri YasudaE-mail: animetokyo-pr@kyodo-pr.co.jpPress release: https://www.acnnewswire.com/docs/files/20250603.pdf Copyright 2025 JCN Newswire via SeaPRwire.com.
Strasbourg, France & Tokyo, Japan, June 2, 2025 - (JCN Newswire via SeaPRwire.com) - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, have presented new positive data on TG4050 in a rapid oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting.These positive data confirm that individualized neoantigen therapeutic vaccine TG4050 is safe and feasible in the adjuvant setting of resectable HPV-negative locally advanced head and neck squamous cell carcinoma (HNSCC). TG4050 induces, as monotherapy, long-lasting immune responses to vaccine neoantigens sustained for up to 2 years, and these results met all trial endpoints (NCT04183166) including safety, feasibility, immune activation and disease-free survival (defined as survival without recurrence or death for any cause).TG4050 is based on Transgene’s myvac® platform and powered by NEC’s cutting-edge AI capabilities designed to optimize antigen selection.Positive data from Phase I, confirming proof of principle of Transgene’s viral vector based individualized cancer vaccine TG4050 in HPV-negative locally advanced head and neck cancer 100% disease free survival at a minimum of 2-year follow-up of treated patients (median follow-up: 30 months) in the Phase I part of the trial: all patients in the TG4050 treatment arm remain disease free while 3 patients in the observational arm have relapsed.Persistence of neoantigen-specific CD8+ T cell responses over 2 years after the start of TG4050 has been observed.Dr. Alessandro Riva, CEO of Transgene, commented: "The sustained clinical and immunogenicity outcomes observed over two years of TG4050 monotherapy, along with the positive safety profile, mark an important milestone for Transgene. These results reinforce both the clinical promise of TG4050 and our commitment to accelerate the development of this individualized immunotherapy in adjuvant setting for patients with HPV-negative, locally advanced head and neck cancer."Motoo Nishihara, Corporate EVP and CTO at NEC, commented: "This positive readout, combined with the durability of the efficacy data at two years, underscore the clinical potential of individualized cancer vaccine programs. It is a strong validation of our innovative AI platform and our dedication to advancing solutions that deliver meaningful, long-term value to patients and healthcare systems alike."Ongoing Phase II part of Phase I/II clinical trial of individualized neoantigen therapeutic cancer vaccine TG4050TG4050 is being evaluated in a randomized multicenter Phase I/II trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (NCT04183166). Based on the promising data obtained in the Phase I part of the trial, Transgene and NEC extended the joint development of TG4050 in this indication with a Phase II extension of the trial.The Phase II part of the trial, aimed at confirming the encouraging results in a larger patient population and evaluating both immunological and clinical outcomes, is currently underway. All patients are expected to be randomized by Q4 2025. Altogether, the Phase I/II study will comprise approximately 80 patients.A conference call in English is scheduled June 6, 2025, at 3:00 p.m. CET. (9:00 a.m. ET)Webcast link to English language conference call: https://edge.media-server.com/mmc/p/x49uzc62 Please log in to the following link to obtain your personal telephone IDs: https://register-conf.media-server.com/register/BId8c981041ca84dad92bb2faa73fc5344 A replay of the call will be available on the Transgene website (www.transgene.com) following the live event.About TransgeneTransgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company’s clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company’s lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities.With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.With its proprietary platform Invir.IO®, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.Additional information about Transgene is available at: www.transgene.com Follow us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @TransgeneAbout myvac®myvac® is a viral vector (MVA – Modified Vaccinia Ankara) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. myvac®-derived products are designed to stimulate the patient’s immune system to recognize and destroy tumors using their own cancer specific genetic mutations. Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities. Transgene has been awarded "Investment for the Future" funding from Bpifrance for the development of its platform myvac®. TG4050 is the first myvac®-derived product being evaluated in clinical trials. Click here to watch a short video on myvac.About TG4050TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgene’s myvac® technology and powered by NEC’s longstanding artificial intelligence (AI) and machine learning (ML) expertise. This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC’s Neoantigen Prediction System. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary data allowing it to accurately prioritize and select the most immunogenic sequences.TG4050 is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens. This individualized immunotherapy is developed and produced for each patient.About the Phase I/II clinical trialTG4050 is being evaluated in a Phase I/II clinical trial for patients with HPV-negative head and neck cancers (NCT04183166). An individualized treatment is created for each patient after they complete surgery and while they receive adjuvant therapy. Half of the participants received their vaccine immediately after completing adjuvant treatment. The other half were given TG4050 as an additional treatment at the time of recurrence of the disease as an additional treatment to standard of care (SoC). This randomized study is evaluating the treatment benefits of TG4050 in patients who are at risk of relapse. In the Phase I part, thirty-two evaluable patients have been included. The Phase II part is currently enrolling patients internationally.About NEC’s Neoantigen Prediction SystemNEC’s neoantigen prediction system utilizes its proprietary AI, such as graph-based relational learning, trained on multiple sources of biological data to discover candidate neoantigen targets. These targets are carefully analyzed using proprietary machine learning algorithms that include in-house HLA binding and antigen presentation AI tools to evaluate the likelihood of eliciting a robust and clinically relevant T-cell response. With NEC OncoImmunity now on board, NEC continues to strengthen its top-class neoantigen prediction pipelines with the aim of maximizing the therapeutic benefits of personalized cancer immunotherapy for patients worldwide.For more information, please visit NEC Bio at https://www.nec-bio.com or https://www.nec-bio.com/en_DD/research-and-innovation/our-approach/ About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential.For more information, visit NEC at https://www.nec.com. DisclaimerThis press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document, available on the AMF website (https://www.amf-france.org) or on Transgene’s website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Copyright 2025 JCN Newswire via SeaPRwire.com.
TOKYO, June 2, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. announced today the launch of “Pariet®S” (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn andstomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan.(1)"Pariet S" is the first proton pump inhibitor (PPI(2)) to receive manufacturing and marketing approval as an over the counter (OTC) medicine in Japan. Rabeprazole sodium, in an amount equivalent to that used in the prescription product(3), works directly on the proton pumps that produce stomach acid, effectively alleviating severe heartburn caused by gastric acid reflux and stomach pain due to excessiveacid secretion. The medicine comes in small, easy-to-swallow tablets, with a once-daily dosage providing 24-hour relief.Rabeprazole sodium, the active ingredient in “Pariet S”, is a PPI developed at Eisai’s Tsukuba Research Laboratories. The medicine was first launched in Japan in 1997 as a prescription pharmaceutical underthe brand name “Pariet” and has since been approved more than 100 countries worldwide. It is widely prescribed to people struggling with acid-related disorders.In recent years, there is a tendency for increased stomach acid secretion due to disrupted eating habits, stress, and a decline in the infection rate of Helicobacter pylori. Moreover, the number of individuals experiencing gastric acid reflux has grown, driven by age-related weakening of the lower esophageal sphincter. Eisai will introduce “Pariet S” as a new treatment option in the OTC gastric medication market, aiming to alleviate sever heartburn and discomfort caused by gastric acid related conditions, and strongly support people in the daily living domain who wish for a comfortable and secure daily life.For further details, please refer to the product’s website for details about "Pariet S" (Japanese only) https://www.eisai.jp/products/pariet/pariets(1) "Pariet S" is classified as a drug that requires a pharmacist’s guidance at the time of sale(2) Proton Pump Inhibitor suppresses gastric acid secretion by inhibiting the “proton pump” which is the final step in the secretion process.(3) Contains rabeprazole10mg per tabletMedia Inquiries:Public Relations DepartmentEisai Co., Ltd.+81-(0)3-3817-5120 Copyright 2025 JCN Newswire via SeaPRwire.com.
HKTDC Chairman Professor Frederick Ma Si-Hang (centre right) met with Executive Director Margaret Fong (centre left) and the management team today (2 June).HONG KONG, Jun 2, 2025 - (ACN Newswire via SeaPRwire.com) – Professor Frederick Ma, the newly appointed Chairman of the Hong Kong Trade Development Council (HKTDC), assumed office on 1 June and met with the management team this morning. Professor Ma said, "It is both an honour and a tremendous responsibility to take up the chairmanship at this juncture of Hong Kong's economic transformation. While I am delighted to contribute to deepening Hong Kong's integration into the national development agenda, the unprecedented challenges of our era compel me to remain vigilant in leveraging Hong Kong's unique roles as a 'super-connector' and 'super-value-adder'." "I am confident that through the collective efforts of the HKTDC team, we will strengthen Hong Kong's core advantages as a global trading and international financial hubs while serving as a bridge linking the Mainland and global markets. Simultaneously, we will proactively explore emerging markets, drive enterprise innovation, sustainable development and digital transformation. This will ensure Hong Kong's enduring vitality on the global trading stage." Biography of HKTDC Chairman Professor Fredrick Ma: https://bit.ly/4mIEHBI Photo download: https://bit.ly/3SRqDZ3Professor Frederick Ma Si-Hang assumed the chairmanship of the HKTDC on 1 JuneMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Agnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgSam HoTel: (852) 2584 4569Email: sam.sy.ho@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.
Caption: NEXX signs joint Memorandums of Understanding (MoU) with Milaha and KEC.(From left to right) Mr. Oscar Hui (CEO of NEXX), Mr. Fahad bin Saad Al-Qahtani (GCEO of Milaha) and Mr. Kevin Lam (Director of KEC)HONG KONG, Jun 2, 2025 - (ACN Newswire via SeaPRwire.com) – NEXX, a leading AI logistics company based in Hong Kong, is excited to announce the signing of joint Memorandums of Understanding (MoUs) with Qatar Navigation Q.P.S.C. ("Milaha") and KEC (Hong Kong) ("KEC"), to advance innovative logistics solutions and capture the growing e-commerce market in Qatar.Mr. Fahad bin Saad Al-Qahtani, GCEO of Milaha, stated: "Our partnerships with NEXX and KEC mark a significant step in Milaha’s transformation journey. By combining NEXX’s advanced AI and automation technologies with KEC’s extensive cross-border e-commerce expertise, we are unlocking powerful synergies that will enhance our logistics capabilities, expand our global reach, and strengthen Qatar’s position as a regional and international logistics hub. These MoUs reflect our commitment to innovation, operational excellence, and supporting the national vision for economic diversification."The MoU with Milaha focuses on the deployment of cutting-edge AI-driven automation technologies at Milaha Logistics City (MLC). This partnership aims to facilitate Milaha’s transition to semi- and fully automated warehousing operations in critical areas such as picking, sorting, forecasting, and order fulfillment. By leveraging NEXX’s mature AI solutions, we will enhance operational efficiency, predictive inventory planning, and order accuracy, establishing a smart and scalable logistics model.Frankie Choy, Managing Director of KEC, stated: “As the e-commerce market in the MENA region continues to expand rapidly, the demand for efficient cross-border logistics and last-mile delivery services is surging. Together with Milaha and NEXX, we are well-positioned to meet this growing demand and deliver exceptional services to our customers.”Through the MoU with KEC, we aim to develop logistics corridors that connect China, Europe and the MENA region, solidifying Qatar’s role as a key hub for fulfillment and cross-border distribution. Our collaboration will capitalize on KEC’s extensive e-commerce expertise and diverse customer base to harness opportunities in the global e-commerce market.As part of this partnership, NEXX and Milaha will work on establishing a dual supply chain hub linking Doha and Hong Kong, enhancing Qatar’s integration into global e-commerce networks. Key innovations will include AI-powered warehouse automation, productivity and safety management systems, and infrastructure enhancements to support bonded, pharmaceutical, and cold storage operations.Oscar Hui, CEO of NEXX, added: “The establishment of a smart fulfillment center in Milaha Logistics City will transform the region’s logistics sector. Our collaboration combines state-of-the-art AI with top-tier logistics services, creating a comprehensive solution that prioritizes customer-centric delivery.”By addressing current gaps in automation and optimizing space utilization, particularly in bonded and cold storage areas, NEXX is committed to enhancing its logistics portfolio across high-growth verticals. This initiative aligns with Qatar National Vision 2030 for economic diversification and supports the Belt and Road Initiative. Caption: Mr. Fahad bin Saad Al-Qahtani (right) presented a souvenir to Mr. Oscar Hui (left), symbolizing that everyone sets sail towards success. Caption: NEXX, Milaha and KEC teams attended and witnessed the signing ceremony. Caption: KLN Chief Operating Officer – EMEA Region, Mr. Darren Baker (first of right) and KEC Director, Mr. Kevin Lam (third from left) led a delegation to join the signing ceremony in Qatar.Images Download: https://bit.ly/3HffFtMAbout NEXXNEXX is a Hong Kong-based AI logistics company, supported by a commercial and R&D hub in Doha, delivering cutting edge logistics solutions across the Greater Bay Area (GBA), Middle East & North Africa (MENA), and Europe. NEXX specializes in industry-focused Agentic AI, a technology designed to automate real-world warehouse tasks with limited human oversight. With Cheung Kong Asset (1113.HK) as a strategic shareholder, the company is driving innovation to enhance supply chain and warehouse efficiency for the ever-changing industry.About MilahaThe company was established in July 1957 as the first public shareholding company registered in Qatar and holds commercial registration no. 1. Milaha’s current activities include marine transportation in gas, petroleum products, containers, and bulk; offshore support services; warehousing, port management and operations; logistics services; shipyard; trading agencies; real estate investments; and asset management.About KEC / KLN Logistics Group Limited (Stock Code 0636.HK)KEC is a subsidiary of KLN Logistics Group Limited (”KLN”), an Asia-based, global 3PL with a highly diversified business portfolio and extensive coverage in Asia. It offers a broad range of supply chain solutions from integrated logistics, international freight forwarding (air, ocean, road, rail and multimodal) and e-commerce to industrial project logistics and infrastructure investment.With a global presence across 59 countries and territories, KLN has established a solid foothold in half of the world’s emerging markets. Its diverse infrastructure, extensive coverage in international gateways and local expertise span across the Mainland of China, India, Southeast Asia, the CIS, Middle East, LATAM and other locations.KLN generated revenue* of close to HK$60 billion in 2024. It is listed on the Hong Kong Stock Exchange and is a constituent of the Hang Seng Corporate Sustainability Benchmark Index.* For continuing operations onlyFor Press EnquiriesStrategic Financial Relations LimitedVeron Ng Tel:(852) 2864 4831Shelly Cheng Tel:(852) 2864 4857Carol Cheung Tel:(852) 2114 2200Email: sprg_reitar@sprg.com.hkNEXXMs. Crystal YipTel: 9587 3234 / 3461 3661Email:crystalyip@nexx-global.comMs. Chelsie TamTel: 6094 3336 / 3461 3750Email:chelsietam@nexx-global.com Copyright 2025 ACN Newswire via SeaPRwire.com.
SINGAPORE, June 2, 2025 - (ACN Newswire via SeaPRwire.com) - Bestselling author, internationally acclaimed motivational speaker, and thought leader Mr. Shiv Khera officially launched his latest book “Live While You’re Alive,” at a grand event. The book was unveiled graciously by His Excellency Dr. Shilpak Ambule, High Commissioner of India to Singapore, marking a significant cultural and literary occasion in the city-state. Adding to the occasion’s prestige were eminent personalities such as Mr. Inderjit Singh, former Member of Parliament, and Mr. K. V. Rao, Chairman of Tata Consultancy. The event drew more than 300 distinguished guests comprising dignitaries, business leaders and educators, all eager to engage with Mr. Khera’s inspiring life-changing message.“Live While You’re Alive" book by Shiv Khera (3rd from L) launched by His Excellency Dr. Shilpak Ambule, High Commissioner of India to Singapore (2nd from L) along with dignitaries and familyDuring the event, Mr. Shiv Khera spoke passionately about the core themes of his new book, which focuses on how stress, when unchecked, can severely impact a person’s health, wealth, and relationships. He emphasized that Stress handling is not just breathing and meditation. It has a lot to do with ATTITUDE. “This book is not just about achieving success,” said Mr. Khera, “but also about avoiding pitfalls. It is a guide to turning stress into strength and living with purpose”The book was earlier launched in India by Dr. S. Jaishankar, Hon’ble Minister of External Affairs, Government of India.With over 15 million copies sold worldwide, including the globally acclaimed “You Can Win,” Shiv Khera continues to inspire individuals and organizations with his messages on attitude, leadership, motivation, and values. His latest book, “Live While You’re Alive (Subtitle – Take a break before you breakdown” offers practical solutions to day-to-day problems.Key insights from the book:Stress is both normal and naturalIt is unavoidableIt cannot be delegatedIf handled properly, it can enhance performance and help achieve new heightsDr. Shilpak Ambule, High Commissioner of India to Singapore, on launching the book, remarked, "Shiv Khera’s 'Live While You’re Alive' is more than just a book—it’s a roadmap to living with purpose and resilience. With his signature inspirational style and practical advice, Khera empowers readers to turn stress into strength and challenges into opportunities. With his signature inspiration style and practical advice, Khera empowers readers to turn stress into strength and challenges into opportunities."The supporting partners present for the launch were — TiE, Indian Women’s Association, IIT Alumni Group, KRISTAL.AI (Digital Private Wealth Management), ICAI, Indian Scholars Association, BIJHAR and Lions Home for the Elders. The book launch event was seamlessly executed by Mett.AI, the official event alliance planner and media coordinator.The event concluded with a dynamic audience Q&A session and a book signing, where attendees had the opportunity to interact directly with Mr. Khera.About Mr Shiv KheraMr Shiv Khera is an author, educator, business consultant, and a much sought-after speaker.He inspires and encourages individuals to realize their true potential. He has taken his dynamic personal messages to opposite sides of the globe, from the U.S. to Singapore. His 40 years of research and understanding has put millions on the path of growth and fulfilment. Over 15 million copies of his books have been sold globally including his international bestseller “You Can Win” in 21 languages. His clients include Lufthansa, HP, DHL, HSBC, Canon, Nestle, Philips, Mercedes, Johnson & Johnson, Metlife, and many more. Tens of thousands have benefitted from his dynamic workshops internationally in over 20 countries and millions have heard him as a Keynote Speaker. He has appeared on numerous radio and television shows. Mr. Khera is the brand ambassador of the Round Table Foundation. He has been honoured by The Lions International and Rotary International. His trademark is: Winners don’t do different things; They do things differently. (https://shivkhera.com/about/)For media queries contactGanesh SMett.AI Ganesh@mettai.world Copyright 2025 ACN Newswire via SeaPRwire.com.
(SeaPRwire) - 联邦调查局将科罗拉多州的这起事件视为恐怖袭击
周日，一名身份不明的男子在科罗拉多州博尔德市被拘留，此前他向支持被哈马斯在加沙扣押的以色列人质的示威者投掷了莫洛托夫鸡尾酒。
现场视频显示，一名赤膊男子携带疑似装有易燃液体的瓶子，同时高呼支持巴勒斯坦的口号。随后，他被看到躺在地上，警察正在逮捕他。
“我们已经意识到并正在全面调查科罗拉多州博尔德市发生的一起有针对性的恐怖袭击。我们的特工和当地执法部门已经在现场，我们将分享更多信息，” FBI 主任 Kash Patel 在 X 上说。
博尔德警察局长 Stephen Redfearn 说，警官们接到报告称，一名嫌疑人“放火烧人”。他证实，有几人已住院治疗，伤势“从非常严重到较轻微不等”。
A pro-Hamas domestic terrorist threw molotov cocktails at some pro-Israel demonstrators in Boulder, Colorado.From the violence on campuses across the country, to violence on our streets, it's past time these thugs were labeled as domestic terrorists.— Leftism (@LeftismForU)
BREAKING: SUSPECT IDENTIFIED as Mohamad Soliman in the Boulder terror attack showsHe was shouting pro-Palestine propaganda with a thick accent.THIS IS WHY WE NEED MASS DEPORTATIONS. These people SHOULD NOT BE HERE.Multiple victims have been life-flighted from the area, and… — Alma Gentil (@Chinoy200096633)
自 2023 年 10 月哈马斯和以色列之间的战争爆发以来，许多国家都发生了支持巴勒斯坦和以色列的激烈示威活动。美国出现了一波反犹太主义事件，亲巴勒斯坦活动人士将目标对准犹太机构和支持以色列的示威者。
上个月，一名高呼支持巴勒斯坦口号的男子在华盛顿市中心 Capital Jewish Museum 外枪杀了以色列大使馆的两名工作人员。
本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。
分类: 头条新闻,日常新闻
SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
```
